Immatics NV (IMTX)

Currency in USD
6.65
+0.04(+0.61%)
Closed·
After Hours
6.650.00(0.00%)
·
IMTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 7 days
Fair Value
Day's Range
6.516.66
52 wk Range
3.3013.09
Key Statistics
Prev. Close
6.61
Open
6.6
Day's Range
6.51-6.66
52 wk Range
3.3-13.09
Volume
240.45K
Average Volume (3m)
614.36K
1-Year Change
-43.07%
Book Value / Share
4.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.33
Upside
+115.54%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Immatics NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Immatics NV Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Compare IMTX to Peers and Sector

Metrics to compare
IMTX
Peers
Sector
Relationship
P/E Ratio
−31.0x−1.1x−0.5x
PEG Ratio
−0.400.000.00
Price/Book
1.3x0.9x2.6x
Price / LTM Sales
4.8x7.0x3.3x
Upside (Analyst Target)
119.4%193.4%43.5%
Fair Value Upside
Unlock35.8%6.3%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.33
(+115.54% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.33 / -0.2567
Revenue / Forecast
18.60M / 17.53M
EPS Revisions
Last 90 days

IMTX Income Statement

People Also Watch

20.23
TDC
-0.66%
3.66
ALT
+2.23%
16.75
SRPT
-2.06%
2.41
IBRX
0.00%
25.89
CNC
-1.22%

FAQ

What Stock Exchange Does Immatics NV Trade On?

Immatics NV is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Immatics NV?

The stock symbol for Immatics NV is "IMTX."

What Is the Immatics NV Market Cap?

As of today, Immatics NV market cap is 803.45M.

What Is Immatics NV's Earnings Per Share (TTM)?

The Immatics NV EPS (TTM) is -0.20.

When Is the Next Immatics NV Earnings Date?

Immatics NV will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is IMTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Immatics NV Stock Split?

Immatics NV has split 0 times.

How Many Employees Does Immatics NV Have?

Immatics NV has 646 employees.

What is the current trading status of Immatics NV (IMTX)?

As of 05 Aug 2025, Immatics NV (IMTX) is trading at a price of 6.65, with a previous close of 6.61. The stock has fluctuated within a day range of 6.51 to 6.66, while its 52-week range spans from 3.30 to 13.09.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.